Alterity Therapeutics Stock Analysis
ATHE Stock | USD 3.94 0.16 4.23% |
Alterity Therapeutics is undervalued with Real Value of 5.06 and Target Price of 9.0. The main objective of Alterity Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Alterity Therapeutics is worth, separate from its market price. There are two main types of Alterity Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Alterity Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Alterity Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Alterity |
Alterity Stock Analysis Notes
The company recorded a loss per share of 1.51. Alterity Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 9th of January 2023. Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimers disease, Huntington disease, Parkinsons disease, and other neurological disorders in Australia. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Alterity Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. For more info on Alterity Therapeutics please contact the company at 61 3 9349 4906 or go to https://alteritytherapeutics.com.Alterity Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Alterity Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Alterity Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Alterity Therapeutics is way too risky over 90 days horizon | |
Alterity Therapeutics appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 4.02 M. Net Loss for the year was (19.12 M) with profit before overhead, payroll, taxes, and interest of 3.54 M. | |
Alterity Therapeutics currently holds about 34.81 M in cash with (12.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87. | |
Alterity Therapeutics has a poor financial position based on the latest SEC disclosures | |
Latest headline from news.google.com: JPMorgan Chase Acquires Significant Stake in Alterity Therapeutics - TipRanks |
Alterity Largest EPS Surprises
Earnings surprises can significantly impact Alterity Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-08-30 | 2021-06-30 | -0.1718 | -0.1334 | 0.0384 | 22 | ||
2019-02-28 | 2018-12-31 | -0.27 | -0.0036 | 0.2664 | 98 | ||
2018-08-31 | 2018-06-30 | -0.28 | -0.0036 | 0.2764 | 98 |
Alterity Therapeutics Environmental, Social, and Governance (ESG) Scores
Alterity Therapeutics' ESG score is a quantitative measure that evaluates Alterity Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Alterity Therapeutics' operations that may have significant financial implications and affect Alterity Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Alterity Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Corecap Advisors, Llc | 2024-09-30 | 0.0 |
Alterity Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.28 M.Alterity Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.90) | (0.94) | |
Return On Capital Employed | (1.63) | (1.55) | |
Return On Assets | (1.14) | (1.20) | |
Return On Equity | (1.59) | (1.51) |
Management Efficiency
Alterity Therapeutics has return on total asset (ROA) of (0.7837) % which means that it has lost $0.7837 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5577) %, meaning that it created substantial loss on money invested by shareholders. Alterity Therapeutics' management efficiency ratios could be used to measure how well Alterity Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 16, 2025, Return On Tangible Assets is expected to decline to -0.94. The current year's Return On Capital Employed is expected to grow to -1.55. At present, Alterity Therapeutics' Fixed Asset Turnover is projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.20, whereas Total Current Assets are forecasted to decline to about 18.7 M.Last Reported | Projected for Next Year | ||
Enterprise Value Over EBITDA | (0.27) | (0.28) | |
Price Book Value Ratio | 1.19 | 1.25 | |
Enterprise Value Multiple | (0.27) | (0.28) | |
Price Fair Value | 1.19 | 1.25 | |
Enterprise Value | 6.6 M | 6.3 M |
Examining the leadership quality of Alterity Therapeutics offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Technical Drivers
As of the 16th of March 2025, Alterity Therapeutics shows the Mean Deviation of 5.78, downside deviation of 5.36, and Risk Adjusted Performance of 0.1271. Alterity Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Alterity Therapeutics treynor ratio, as well as the relationship between the potential upside and expected short fall to decide if Alterity Therapeutics is priced correctly, providing market reflects its regular price of 3.94 per share. Given that Alterity Therapeutics has jensen alpha of 1.43, we suggest you to validate Alterity Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.Alterity Therapeutics Price Movement Analysis
The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Alterity Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Alterity Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Alterity Therapeutics Outstanding Bonds
Alterity Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alterity Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alterity bonds can be classified according to their maturity, which is the date when Alterity Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Altice France 8125 Corp BondUS02156LAA98 | View | |
ALTICE FRANCE S Corp BondUS02156LAE11 | View | |
Altice France 55 Corp BondUS02156LAC54 | View | |
US02156LAH42 Corp BondUS02156LAH42 | View | |
US02156LAF85 Corp BondUS02156LAF85 | View | |
Altice Europe 5 Corp BondUS02154CAF05 | View | |
US02154CAH60 Corp BondUS02154CAH60 | View | |
Altice Europe 105 Corp BondUS02156TAB08 | View |
Alterity Therapeutics Predictive Daily Indicators
Alterity Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Alterity Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Alterity Therapeutics Corporate Filings
6K | 14th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 28th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 24th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 19th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 18th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 10th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 6th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 5th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Alterity Therapeutics Forecast Models
Alterity Therapeutics' time-series forecasting models are one of many Alterity Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alterity Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Alterity Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Alterity Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Alterity shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Alterity Therapeutics. By using and applying Alterity Stock analysis, traders can create a robust methodology for identifying Alterity entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (5.46) | (5.73) | |
Operating Profit Margin | (5.61) | (5.89) | |
Net Loss | (5.47) | (5.75) | |
Gross Profit Margin | 1.09 | 1.03 |
Current Alterity Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Alterity analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Alterity analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
9.0 | Strong Buy | 2 | Odds |
Most Alterity analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Alterity stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Alterity Therapeutics, talking to its executives and customers, or listening to Alterity conference calls.
Alterity Stock Analysis Indicators
Alterity Therapeutics stock analysis indicators help investors evaluate how Alterity Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Alterity Therapeutics shares will generate the highest return on investment. By understating and applying Alterity Therapeutics stock analysis, traders can identify Alterity Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 15.8 M | |
Total Stockholder Equity | 13.8 M | |
Capital Lease Obligations | 159 K | |
Property Plant And Equipment Net | 186.9 K | |
Cash And Short Term Investments | 12.6 M | |
Net Invested Capital | 13.8 M | |
Cash | 12.6 M | |
50 Day M A | 3.8326 | |
Net Interest Income | 268.4 K | |
Total Current Liabilities | 5.4 M | |
Investments | -5722.00 | |
Stock Based Compensation | 882 K | |
Common Stock Shares Outstanding | 3.6 B | |
Tax Provision | 46.1 K | |
Free Cash Flow | -12.6 M | |
Operating Income | -19.6 M | |
Other Current Assets | 2.4 M | |
Accounts Payable | 581.1 K | |
Net Debt | -12.5 M | |
Depreciation | 147.5 K | |
Other Operating Expenses | 23.6 M | |
Non Current Assets Total | 186.9 K | |
Liabilities And Stockholders Equity | 19.2 M | |
Home Category | ADR |
Complementary Tools for Alterity Stock analysis
When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |